603 related articles for article (PubMed ID: 29977059)
1. Ewing sarcoma.
Grünewald TGP; Cidre-Aranaz F; Surdez D; Tomazou EM; de Álava E; Kovar H; Sorensen PH; Delattre O; Dirksen U
Nat Rev Dis Primers; 2018 Jul; 4(1):5. PubMed ID: 29977059
[TBL] [Abstract][Full Text] [Related]
2. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
3. Adamantinoma-like Ewing Sarcoma of the thyroid gland: Cytomorphologic, phenotypic and molecular features.
Chikeka I; Sung S; Tiscornia-Wasserman P; Cimic A
Diagn Cytopathol; 2020 Nov; 48(11):1107-1110. PubMed ID: 32472960
[TBL] [Abstract][Full Text] [Related]
4. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.
Grünewald TG; Bernard V; Gilardi-Hebenstreit P; Raynal V; Surdez D; Aynaud MM; Mirabeau O; Cidre-Aranaz F; Tirode F; Zaidi S; Perot G; Jonker AH; Lucchesi C; Le Deley MC; Oberlin O; Marec-Bérard P; Véron AS; Reynaud S; Lapouble E; Boeva V; Rio Frio T; Alonso J; Bhatia S; Pierron G; Cancel-Tassin G; Cussenot O; Cox DG; Morton LM; Machiela MJ; Chanock SJ; Charnay P; Delattre O
Nat Genet; 2015 Sep; 47(9):1073-8. PubMed ID: 26214589
[TBL] [Abstract][Full Text] [Related]
5. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA.
Hayashi M; Chu D; Meyer CF; Llosa NJ; McCarty G; Morris CD; Levin AS; Wolinsky JP; Albert CM; Steppan DA; Park BH; Loeb DM
Cancer; 2016 Oct; 122(19):3015-23. PubMed ID: 27351911
[TBL] [Abstract][Full Text] [Related]
6. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma.
Koelsche C; Kriegsmann M; Kommoss FKF; Stichel D; Kriegsmann K; Vokuhl C; Grünewald TGP; Romero-Pérez L; Kirchner T; de Alava E; Diaz-Martin J; Hartmann W; Baumhoer D; Antonescu CR; Szuhai K; Flucke U; Dirksen U; Pfister SM; Jones DTW; Mechtersheimer G; von Deimling A
J Cancer Res Clin Oncol; 2019 May; 145(5):1273-1281. PubMed ID: 30895378
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors.
Tomlins SA; Palanisamy N; Brenner JC; Stall JN; Siddiqui J; Thomas DG; Lucas DR; Chinnaiyan AM; Kunju LP
Am J Clin Pathol; 2013 Jun; 139(6):771-9. PubMed ID: 23690120
[TBL] [Abstract][Full Text] [Related]
9. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
10. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
[TBL] [Abstract][Full Text] [Related]
11. Small round cell sarcomas.
Cidre-Aranaz F; Watson S; Amatruda JF; Nakamura T; Delattre O; de Alava E; Dirksen U; Grünewald TGP
Nat Rev Dis Primers; 2022 Oct; 8(1):66. PubMed ID: 36202860
[TBL] [Abstract][Full Text] [Related]
12. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
13. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
14. STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma.
Surdez D; Zaidi S; Grossetête S; Laud-Duval K; Ferre AS; Mous L; Vourc'h T; Tirode F; Pierron G; Raynal V; Baulande S; Brunet E; Hill V; Delattre O
Cancer Cell; 2021 Jun; 39(6):810-826.e9. PubMed ID: 33930311
[TBL] [Abstract][Full Text] [Related]
15. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
17. EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival.
Gallegos ZR; Taus P; Gibbs ZA; McGlynn K; Gomez NC; Davis I; Whitehurst AW
Mol Cell Biol; 2019 Jul; 39(14):. PubMed ID: 31036566
[TBL] [Abstract][Full Text] [Related]
18. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.
Riggi N; Knoechel B; Gillespie SM; Rheinbay E; Boulay G; Suvà ML; Rossetti NE; Boonseng WE; Oksuz O; Cook EB; Formey A; Patel A; Gymrek M; Thapar V; Deshpande V; Ting DT; Hornicek FJ; Nielsen GP; Stamenkovic I; Aryee MJ; Bernstein BE; Rivera MN
Cancer Cell; 2014 Nov; 26(5):668-681. PubMed ID: 25453903
[TBL] [Abstract][Full Text] [Related]
19. Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational Modifications.
Yu L; Davis IJ; Liu P
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672331
[TBL] [Abstract][Full Text] [Related]
20. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
